Pancreatic cancer: The RAS paradigm shift

Pancreatic Cancer: The RAS Paradigm Shift – An Evidence Dossier Source: PLOS Medicine, article published October 29, 2026, by Samuel P. Soff and Eileen M. O’Reilly What is Established Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the deadliest cancers, with a five-year survival rate near 13%. It often presents late…

Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial

Immunogenicity and Safety of Shorter Intradermal Rabies Vaccine Regimens in India: Evidence from a Phase 4 Trial Rabies remains a fatal viral disease with significant public health impact worldwide, especially in India, which bears a large proportion of the global burden. Post-exposure prophylaxis (PEP) through anti-rabies vaccination is critical for preventing rabies…

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 77, Status: Authorised

Opdivo (Nivolumab) – European Public Assessment Report Evidence Dossier What is established Opdivo, whose active substance is nivolumab, is an immune checkpoint inhibitor authorized by the European Medicines Agency (EMA) for the treatment of several advanced cancers. Opdivo targets PD-1, a receptor on immune T cells, preventing cancer cells from switching off…

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 19, Status: Authorised

Qarziba (Dinutuximab beta) for Neuroblastoma: An Evidence Dossier What is established Qarziba is a medicinal treatment authorised in the European Union for the management of neuroblastoma, a cancer of nerve cells primarily affecting children older than one year. It was granted marketing authorisation under exceptional circumstances by the European Medicines Agency (EMA)…

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 19, Status: Authorised

What is established Carvykti (ciltacabtagene autoleucel) is a genetically engineered therapy approved in the European Union for the treatment of multiple myeloma, a type of bone marrow cancer. It is authorized for adult patients whose disease has relapsed or is refractory following at least one prior treatment line that included an immunomodulatory…

How IRL Story Lab is Reimagining What Journalism Can Do

Investigative Reporting Lab Turns Journalism Into Award-Winning Fiction to Engage New Audiences What is established The Investigative Reporting Lab (IRL), a North Macedonian media and member of the Organized Crime and Corruption Reporting Project (OCCRP), has launched an innovative approach to investigative journalism by adapting its reporting into fictional films. Their first…

First public health emergency preparedness assessments across Europe show both commitment and recurring challenges

Evidence Dossier: Public Health Emergency Preparedness in Europe What is established The European Centre for Disease Prevention and Control (ECDC), in collaboration with the European Commission, the World Health Organization (WHO) Regional Office for Europe, and other partners, conducted for the first time a comprehensive Public Health Emergency Preparedness Assessment (PHEPA) cycle…

Veterinary medicines European public assessment report (EPAR): Cirbloc, porcine circovirus vaccine (inactivated), Status: Authorised

Health & Science Evidence Dossier: Cirbloc Porcine Circovirus Vaccine (Inactivated) What is established The European Medicines Agency (EMA) has authorised a veterinary medicinal product named Cirbloc, which is an inactivated vaccine developed to protect pigs against porcine circovirus type 2d (PCV2d). This vaccine employs the ORF2 capsid protein of PCV2d as its…